Slides
Page 1
Q2 FY27 Earnings Presentation 30th Oct 2026 NSE:SUNPHARMA | BSE:524715 | Bloomberg:SUNP IN | Reuters:SUN.BO WWW.SUNPHARMA.COM Annexure-C
Page 2
Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward- looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Sun Pharmaceutical Industries Limited does not undertake any obligation to update forward- looking statements to reflect events or circumstances after the date thereof. Disclaimer © Sun Pharmaceutical Industries Limited. All Rights Reserved. 2
Page 3
© Sun Pharmaceutical Industries Limited. All Rights Reserved. 3 Performance Update Innovative Medicine Focus Financial Prudence Sales Growth for Q2 at 11.8%, & H1 at 11.0% EBITDA Margin for the quarter at 29.3%, and 29.1% for H1FY27 Growth in India, EM and RoW supported growth Global Innovative Medicines delivers 6.9% growth for the quarter Ilumya approved in the US for treatment of adults with active psoriatic arthritis Unloxcyt gets preferred NCCN recommendation Acquired rights to lerodalcibep for ex-US, ex- China Strong balance sheet, with Net Cash position of US$ 3.3 bn Successful allotment of debut non-convertible debentures of ₹7,816 Cr. Performance Highlights
Page 4
© Sun Pharmaceutical Industries Limited. All Rights Reserved. 4 (₹ mn) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Sales 1,61,000 1,44,052 11.8% 3,12,836 2,81,913 11.0% Gross Margin % 80.8% 79.3% 80.6% 79.4% EBITDA 47,439 45,271 4.8% 91,616 88,287 3.8% EBITDA% 29.3% 31.3% 29.1% 31.2% Reported PAT 19,885 31,180 48,833 53,966 Adjusted PAT 31,620 31,180 1.4% 62,515 61,141 2.2% EPS 8.3 13.0 20.4 22.5 Q2FY27 : Sales of ₹ 161.0 bn, 11.8% growth over last year, with Profit After Tax of ₹ 19.8 bn H1FY27 : Sales of ₹ 312.8 bn, 11.0% growth over last year, with Profit After Tax of ₹ 48.8 bn Financial Snapshot
Page 5
India, 35% US, 27% EM, 21% RoW, 14% API & Others, 3% © Sun Pharmaceutical Industries Limited. All Rights Reserved. ₹ 161 bn Q2FY27 Sales Revenue Snapshot Note: Numbers shown are Sales excluding Other Operating Revenue 5 India 35% US 27% EM 20% RoW 14% API & Others 4% ₹ 312 bn H1FY27 Sales Q2FY27 H1FY27
Page 6
644 707 H1FY26 H1FY27 333 356 Q2FY26 Q2FY27 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 6 Innovative Medicines * Source: AIOCD AWACS MAT Mar 2026 ✓ Growth of 6.9% in Q2FY27, driven by both US & international markets ✓ In H1FY27, Innovative Medicines sales touched US$ 707mn, 9.8% growth over last year ✓ Global Innovative Medicines forms 21.1% of the total consolidated sales for Q2FY27 Sales (USD mn)
Page 7
47,348 55,523 Q2FY26 Q2FY27 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 7 Sustained Market Share* Growth India Formulations * Source: AIOCD AWACS MAT Mar 2026 ✓ In Q2, India formulations recorded growth of 17%, and launched 14 new products ✓ Sustained market share growth; 0.3pp gain over the year to reach 8.6% ✓ India Formulations forms 34.5% of total consolidated sales for Q2FY27 Sales (₹ mn) * Market Share as per Pharmarack MAT Sep 2026 94,559 1,10,272 H1FY26 H1FY27 8.3% 8.6% Sep'25 Sep'26
Page 8
968 882 H1FY26 H1FY27 496 455 Q2FY26 Q2FY27 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 8 US Formulations * Source: AIOCD AWACS MAT Mar 2026 ✓ US Formulations declined by 8.2% in Q2FY27, to reach US$ 455 mn ✓ Lenalidomide erosion impact. US sales slightly up ex-lenalidomide for Q2. ✓ US Formulations forms 27% of total consolidated sales for the quarter Sales (USD mn) 70 70 57 58 Q1FY27 Q2FY27 Cumulative NDAs Filed Cumulative NDAs Approved 677 681 558 561 Q1FY27 Q2FY27 Cumulative ANDAs Filed Cumulative ANDAs Approved ANDA Pipeline NDA Pipeline
Page 9
623 661 H1FY26 H1FY27 325 350 Q2FY26 Q2FY27 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 9 Emerging Markets Formulations * Source: AIOCD AWACS MAT Mar 2026 ✓ Emerging Markets recorded Q2FY27 Revenue of US$ 350 mn, 7.6% higher than last year ✓ Emerging Markets Formulations form 20.7% of total consolidated sales for the quarter ✓ Innovative Medicines portfolio continues to drive growth in Emerging Markets Focus Markets Romania Brazil South Africa Mexico Sales (USD mn)
Page 10
453 460 H1FY26 H1FY27 234 241 Q2FY26 Q2FY27 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 10 Rest of World Formulations * Source: AIOCD AWACS MAT Mar 2026 ✓ RoW Formulations recorded Q2FY27 Revenue of US$ 241 mn ✓ RoW Formulations form 14.3% of total consolidated sales for the quarter Sales (USD mn) Focus Markets Western Europe Canada Japan Australia & NZ
Page 11
✓ In Q2FY27, R&D investments were at 4.8% of sales ✓ Of the total R&D spend, 32.4% was for Innovative Medicines R&D © Sun Pharmaceutical Industries Limited. All Rights Reserved. 11 R&D Update Candidate Indication Current phase Next milestone Ilumya psoriatic arthritis Approved in the US Launch Fibromun soft tissue sarcoma Phase 2 completed Start of Phase 3 glioblastoma Phase 2 Regulatory filing GL0034 type 2 diabetes Phase 2 Topline data during 2HCY27 NidlegyTM (EU, ANZ rights with Sun) locally advanced melanoma Filing with EMA Approval and launch locally advanced BCC Phase 3 Regulatory filing locally advanced cSCC Phase 2 Regulatory filing Candidate for partnering MM-II pain in osteoarthritis Phase 2 completed To enter partnership for commercialization
Page 12
© Sun Pharmaceutical Industries Limited. All Rights Reserved. 12 Signed definitive docs with Organon on 27th April 2026 Ongoing deal closure • Organon received Shareholders’ approval on 23rd July 2026 • Approvals received for majority filings; a few pending Sun and Organon will continue to work as independent entities till deal closure Integration Planning post-closing • Integration Management Office working on Day 1 preparedness Indicative closure of proposed transaction by Q4FY27 1 2 3 4 5 Organon Acquisition Update
Page 13
© Sun Pharmaceutical Industries Limited. All Rights Reserved. 13 ESG Update for FY26 • 17.97% gender diversity • 0 fatalities • ₹ 2,068 mn spent on CSR activities • 95.2% Board meeting attendance • 50% Independent board directors • 63% of Board members specializing in pharmaceutical industry experience • 43% energy sourced from renewable sources • 15% reduction in absolute Scope 1 & 2 emissions compared to baseline year 2020 • 16% reduction in absolute water consumption compared to baseline year 2020
Page 14
Thank You Investors Dr. Abhishek Sharma Tel : +91 22 4324 4324, Xtn 2929 Tel Direct +91 22 4324 2929 abhi.sharma@sunpharma.com For more information, please contact © 2017 Sun Pharmaceutical Industries Limited., All Rights Reserved. “SUN Pharma”, The Sun Pharmaceutical Industries Logo are trademarks of Sun Pharmaceutical Industries Limited. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners. Corporate Address SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063 NSE:SUNPHARMA, BSE: 524715, Reuters: SUN.BO, Bloomberg: SUNP IN CIN: L24230GJ1993PLC019050 www.sunpharma.com © Sun Pharmaceutical Industries Limited. All Rights Reserved. 14